Skip to Content

ETH 383 (Carbidopa and levodopa extended release 50 mg / 200 mg)

Pill imprint ETH 383 has been identified as Carbidopa and levodopa extended release 50 mg / 200 mg.

Carbidopa/levodopa is used in the treatment of parkinson's disease; restless legs syndrome; neuroleptic malignant syndrome; gtp-ch deficiency and belongs to the drug class dopaminergic antiparkinsonism agents. Risk cannot be ruled out during pregnancy. Carbidopa/levodopa 50 mg / 200 mg is not a controlled substance under the Controlled Substance Act (CSA).

Carbidopa and levodopa extended release 50 mg / 200 mg ETH 383
Discount Card Promo
Carbidopa and levodopa extended release
ETH 383
50 mg / 200 mg
13.00 mm
Elliptical / Oval
Prescription only
Drug Class:
Dopaminergic antiparkinsonism agents
Pregnancy Category:
C - Risk cannot be ruled out
CSA Schedule:
Not a controlled drug
Ethex Corporation
National Drug Code (NDC):
Inactive Ingredients:
silicon dioxide colloidal
D&C Yellow No. 10
FD&C Red No. 3
fumaric acid
sodium stearyl fumarate

Note: Inactive ingredients may vary.

More info Print Imprint Search

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Copyright 2017, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.